Core Viewpoint - HUTCHMED has successfully renewed contracts with the China National Healthcare Security Administration (NHSA), ensuring the inclusion of its drugs ELUNATE, ORPATHYS, and SULANDA in the updated National Reimbursement Drug List (NRDL) effective January 1, 2026, and the addition of TAZVERIK to the National Commercial Health Insurance Innovative Drug List [1][4]. Group 1: Drug Inclusion and Details - ELUNATE (fruquintinib) is included for treating advanced endometrial cancer with pMMR tumors and metastatic colorectal cancer patients who have undergone prior chemotherapy [2]. - ORPATHYS (savolitinib) is included for adult patients with locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping alteration [3]. - SULANDA (surufatinib) is renewed for treating unresectable, locally advanced or metastatic, progressive non-functional well-differentiated neuroendocrine tumors [3]. - TAZVERIK (tazemetostat) is included in the Commercial Insurance Drug List for adult patients with relapsed or refractory follicular lymphoma with EZH2 mutation [4]. Group 2: Reimbursement Framework - The new Commercial Insurance Drug List, established by the NHSA, focuses on innovative medicines with significant clinical value, enabling reimbursement through various commercial health insurance products [4]. - As of the end of 2024, approximately 1.33 billion people in China had basic medical insurance coverage, representing around 95% of the population, highlighting the government's commitment to improving drug affordability [5]. Group 3: Company Overview - HUTCHMED is an innovative biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [10]. - The company has successfully brought its first three medicines to market in China, with one also approved globally [10].

Core Viewpoint - Innovent Biologics has successfully included seven innovative products in the updated 2025 National Reimbursement Drug List (NRDL), enhancing patient access to critical therapies for major diseases in China [1][2]. Product Summaries - **TYVYT® (sintilimab injection)**: Newly included indication for advanced endometrial cancer in combination with fruquintinib, addressing a significant treatment gap for patients with limited responses to traditional therapies [4][3]. - **SYCUME® (teprotumumab N01 injection)**: First approved IGF-1R antibody drug in China, newly listed for moderate-to-severe thyroid eye disease, significantly improving patient accessibility and affordability [6][5]. - **Limertinib**: Newly listed for treating advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC) and as a first-line treatment for specific EGFR mutations, offering enhanced penetration across the blood-brain barrier [9][8]. - **Dupert® (fulzerasib)**: Newly listed for advanced NSCLC patients with KRAS G12C mutation, providing a novel targeted therapy option [10]. - **DOVBLERON® (taletrectinib)**: Newly listed for locally advanced or metastatic ROS1-positive NSCLC, potentially offering a best-in-class therapy [12][11]. - **Retsevmo® (selpercatinib)**: Newly listed for various indications in NSCLC and thyroid cancer, being the first RET inhibitor approved globally [14][13]. - **Jaypirca® (pirtobrutinib)**: Newly listed for relapsed or refractory mantle cell lymphoma, addressing unmet needs for heavily treated patients [16][15]. Company Overview - Innovent Biologics is a leading biopharmaceutical company founded in 2011, focusing on developing affordable, high-quality medicines for oncology, cardiovascular, metabolic, autoimmune, and ophthalmology diseases [17]. The company has launched 17 products and has multiple assets in various stages of clinical trials [17].